Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?

ABSTRACT: Substantially reduced life expectancy for people with serious mental illness compared with the general population is primarily driven by physical health issues, of which cardiovascular disease is the leading cause. In this narrative review, we examine the evidence base for use of metformin and other antidiabetic agents as a means for reducing this excess cardiometabolic disease burden. Evidence from randomised controlled trials (RCTs) suggests substantial potential for metformin to prevent or manage weight gain and glycaemic impairment induced by atypical antipsychotic medications, whereas the impact of metformin on other cardiometabolic risk factors is less consistent. Evidence from RCTs also suggests potential benefits from glucagon-like peptide-1 receptor agonists (GLP-1RAs), particular

SUBMITTER: Mc Namara KP 

PROVIDER: S-EPMC9828708 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature